IP Library Granted Patent US 9,144,570
Granted Patent B2
US 9,144,570 · App. 13/958,530 · Granted Sep 29, 2015

Method to enhance delivery of glutathione and ATP levels in cells

Inventor: Herbert T. Nagasawa (Irvine, CA)
Assignee: Max International, LLC
A61K31/426A01K67/0271A01K2227/105A01K2267/0331C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,144,570
App. No.
13/958,530
Granted
Sep 29, 2015
Kind
B2
Abstract

A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.

Claims (12)

1. A method of treating a tissue ischemia resulting from a surgical procedure in a mammal in need thereof by increasing glutathione and ATP comprising administering an effective amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid, or a pharmaceutically acceptable salt thereof, to said mammal, wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid increases glutathione and ATP to treat said tissue ischemia resulting from the surgical procedure.

2. The method of claim 1 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered orally or parenterally.

3. The method of claim 1 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered orally.

4. The method of claim 1 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered intravenously.

5. The method of claim 1 , wherein the surgical procedure is angioplasty, stenting, heart surgery, or organ transplantation.

6. The method of claim 1 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered in a unit dosage form comprising 20% (w/w) of RibCys.

7. The method of claim 1 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered in a liquid.

8. The method of claim 7 , wherein said liquid further comprises an effective amount of ribose to inhibit premature dissociation of the 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid.

9. The method of claim 7 , wherein said liquid comprises an effective amount of ribose to inhibit premature in vitro dissociation of the 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid.

10. The method of claim 1 , wherein said method consists of administering an effective amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid or a pharmaceutically acceptable salt thereof to said mammal.

11. The method of claim 2 , wherein said 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidone-4(R)-carboxylic acid is administered intravenously.

12. The method of claim 5 , wherein the heart surgery is heart bypass surgery or heart repair surgery.

Assignments (5)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 5, 2021
From: MAX INTERNATIONAL, LLC
To: EAST WEST BANK
Reel/Frame 058809/0733 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 031409 FRAME 0444. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNOR NAME IS CELLGEVITY, INC. Recorded Oct 17, 2013
From: CELLGEVITY, INC.
To: MAX INTERNATIONAL, LLC
Reel/Frame 031431/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2013
From: NAGASAWA, HERBERT T.
To: BIOCEUTICALS, INC.
Reel/Frame 031409/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2013
From: CELLGIVITY, INC.
To: MAX INTERNATIONAL LLC
Reel/Frame 031409/0444 →
CHANGE OF NAME Recorded Oct 15, 2013
From: BIOCEUTICALS, INC.
To: CELLGEVITY, INC.
Reel/Frame 031412/0234 →
Continuity (3)
Continuation 12182354 · Jul 30, 2008
Continuation 10990933 · Nov 17, 2004
Related Publication 20130317072A1 · Nov 28, 2013